Amarin Corp. PLC (NASDAQ:AMRN) shares fell 1.7% during mid-day trading on Tuesday . The stock traded as low as $2.33 and last traded at $2.34, with a volume of 392,211 shares changing hands. The stock had previously closed at $2.38.

Several research firms have recently issued reports on AMRN. Jefferies Group began coverage on Amarin Corp. PLC in a research note on Thursday, May 12th. They issued a “buy” rating and a $3.50 price objective for the company. Zacks Investment Research downgraded Amarin Corp. PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Amarin Corp. PLC in a research note on Monday, May 9th.

The stock’s market capitalization is $437.13 million. The firm’s 50 day moving average price is $2.19 and its 200-day moving average price is $1.76.

Amarin Corp. PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.03. The firm earned $25.30 million during the quarter, compared to analyst estimates of $26.77 million. During the same period last year, the firm earned ($0.16) earnings per share. Amarin Corp. PLC’s revenue was up 60.4% on a year-over-year basis. On average, analysts forecast that Amarin Corp. PLC will post ($0.49) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Amarin Corp. PLC stock. OppenheimerFunds Inc. increased its stake in shares of Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned 2.90% of Amarin Corp. PLC worth $10,061,000 at the end of the most recent quarter.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.